Updated Phase 1 data presented at the 2026 American Society of Gene and Cell Therapy (ASGCT) meeting suggest that Fate Therapeutics’ off-the-shelf CAR...

The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple...